CSL to Benefit From Immunoglobin Sales Growth, Says Jefferies

MT Newswires Live

Oct 02

CSL (ASX:CSL) is expected to benefit from the anticipated rise in immunoglobulin sales globally, said Jefferies in a Thursday note.

Jefferies added that it believes that the plasma industry remains rational, with the number of US plasma collection centers rising by 7% year-on-year in 2024 and an estimated 7% 2025, and about 5% year-on-year increase in US dollar-denominated inventory in 2024.

The research firm has adjusted its price target for the company for an expected 1% reduction in earnings per share in fiscal 2026 and 7% in fiscal 2027 due to changes in healthcare policies.

Jefferies has a buy rating on CSL a price target of AU$275, down from AU$288.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2572594237"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2572594237\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2572594237?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-02 15:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2572594237","market":"fut","top_or_hot":-1,"title":"CSL to Benefit From Immunoglobin Sales Growth, Says Jefferies","media":"MT Newswires Live","content":"<html><body><p> CSL (ASX:CSL) is expected to benefit from the anticipated rise in immunoglobulin sales globally, said Jefferies in a Thursday note.</p><p>Jefferies added that it believes that the plasma industry remains rational, with the number of US plasma collection centers rising by 7% year-on-year in 2024 and an estimated 7% 2025, and about 5% year-on-year increase in US dollar-denominated inventory in 2024.</p><p>The research firm has adjusted its price target for the company for an expected 1% reduction in earnings per share in fiscal 2026 and 7% in fiscal 2027 due to changes in healthcare policies.</p><p>Jefferies has a buy rating on CSL a price target of AU$275, down from AU$288.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CSL to Benefit From Immunoglobin Sales Growth, Says Jefferies</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCSL to Benefit From Immunoglobin Sales Growth, Says Jefferies\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-10-02 15:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> CSL (ASX:CSL) is expected to benefit from the anticipated rise in immunoglobulin sales globally, said Jefferies in a Thursday note.</p><p>Jefferies added that it believes that the plasma industry remains rational, with the number of US plasma collection centers rising by 7% year-on-year in 2024 and an estimated 7% 2025, and about 5% year-on-year increase in US dollar-denominated inventory in 2024.</p><p>The research firm has adjusted its price target for the company for an expected 1% reduction in earnings per share in fiscal 2026 and 7% in fiscal 2027 due to changes in healthcare policies.</p><p>Jefferies has a buy rating on CSL a price target of AU$275, down from AU$288.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CSL","symbol_name":"卡莱尔伙伴","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2572594237","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2572594237","pubTimestamp":1759388914,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"CSL  is expected to benefit from the anticipated rise in immunoglobulin sales globally, said Jefferies in a Thursday note.Jefferies added that it believes that the plasma industry remains rational, with the number of US plasma collection centers rising by 7% year-on-year in 2024 and an estimated 7% 2025, and about 5% year-on-year increase in US dollar-denominated inventory in 2024.The research firm has adjusted its price target for the company for an expected 1% reduction in earnings per share in fiscal 2026 and 7% in fiscal 2027 due to changes in healthcare policies.Jefferies has a buy rating on CSL a price target of AU$275, down from AU$288.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"CSL":"卡莱尔伙伴","CSL.AU":"CSL LIMITED"},"translate_title":"杰富瑞表示，CSL将受益于免疫球蛋白销售增长","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CSL.AU":1.5,"CSL":1.5},"content_text":"CSL (ASX:CSL) is expected to benefit from the anticipated rise in immunoglobulin sales globally, said Jefferies in a Thursday note.Jefferies added that it believes that the plasma industry remains rational, with the number of US plasma collection centers rising by 7% year-on-year in 2024 and an estimated 7% 2025, and about 5% year-on-year increase in US dollar-denominated inventory in 2024.The research firm has adjusted its price target for the company for an expected 1% reduction in earnings per share in fiscal 2026 and 7% in fiscal 2027 due to changes in healthcare policies.Jefferies has a buy rating on CSL a price target of AU$275, down from AU$288.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}